Case report demonstrates improved prognosis in prostate cancer with pembrolizumab, surgical resection, and radiotherapy.
Pembrolizumab combined with surgical resection, radiotherapy, and systemic chemotherapy may improve the prognosis of patients with treatment-induced large-cell neuroendocrine carcinoma of the prostate, although further accumulation of cases is needed.
No takes yet. Share an insight, caveat, or question.
Yamashita et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: